Oct 29 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP RECEIVES POSITIVE EMA SCIENTIFIC ADVICE FOR FURTHER CLINICAL DEVELOPMENT OF EFTI IN MBC INCLUDING PHASE III
- IMMUTEP LTD - POSITIVE FEEDBACK FOR GENERAL CLINICAL DEVELOPMENT PROGRAM INCLUDING PLANNED REGISTRATIONAL PHASE III TRIAL IN METASTATIC BREAST CANCER
- IMMUTEP LTD - OTHER REGULATORY ENGAGEMENT ONGOING, INCLUDING WITH US FOOD AND DRUG ADMINISTRATION
News: IMM Immutep Receives Positive EMA Scientific Advice For Further Clinical Development Of EFTI...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.3¢ |
Change
-0.038(11.0%) |
Mkt cap ! $443.0M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.0¢ | 29.8¢ | $1.220M | 3.899M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 45672 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 120686 | 16 |
View Market Depth
| Last trade - 14.40pm 05/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |